文章预览
Key takeaways: 1、Genuine Biotech has filed to list in Hong Kong, planning to raise funds to commercialize its newly approved oral Covid drug 2、The company’s Azvudine is the first domestically developed oral Covid-19 drug approved for China, though some still question its effectiveness A little-known drug maker named Genuine Biotech Ltd. wants to strike while the iron is hot, and is rushing to sell investors on its dream of becoming a new rags-to-riches story. That’s the hope, at least, after the company received a conditional regulatory green light on July 25 to sell Azvudine, China’s first self-developed small molecule oral drug for Covid-19 treatment. Just 10 days later, Genuine Biotech filed for a Hong Kong IPO. Adding to the momentum, China’s National Health Commission announced on Aug. 9 that Azvudine had been included among its latest antiviral treatments for Covid, further clearing the way for its commercialization. Oral Covid-19 drugs are quickly bec
………………………………
